Conexiant
Login
  • JADPRO
  • The ASCO Post
  • JNCCN
JADPRO
  • From the Journal
     
    • Online First

    Issues

    • Current
    • Archive
    • Supplements

    Sections

    • Editorial
    • Research and Scholarship
    • Review Article
    • Grand Rounds
    • Practice Matters
    • Prescriber's Corner
    • Diagnostic Snapshot
    • Meeting Report
    • Meeting Abstracts
  • Topics & Conditions

    Solid Tumors

    • Breast Cancer
    • Central Nervous System Cancers
    • Colorectal Cancer
    • View All

    Hematologic Malignancies

    • Leukemia
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • View All

    Issues in Oncology

    • Cardio-Oncology
    • Genomics/Genetics
    • Clinical Trial Design
    • View All

    Supportive Care

    • Symptom Management
    • Pain Management
    • Palliative Care
    • View All

    Developmental Therapeutics

    • CAR T-Cell Therapy
    • Immunotherapy
    • View All
  • Events

    Live Events

    • JADPRO Live

    Webinars

    • JADPRO Clinical Case Series JADPRO Best Practices Summit

    Coverage

    • Newsreels
    • Meeting Hightlights
  • Education

    Educational Resources

    • Newsreels
    • Expert Conversations
    • FDA Focus
    • Patient Education
    • Roundtable Series
    • Meeting Highlights
    • Resource Centers
  • Multimedia
    • Podcasts
    • Videos
  • About
Subscribe Submission
Submissions Subscribe
JADPRO / Education / FDA Focus / Vyloy Zolbetuximab-clzb from Astellas Pharma US

Vyloy (zolbetuximab-clzb) with fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma

October 18, 2024

Initial US Approval:

2024

Key Clinical Studies:

SPOTLIGHT (NCT03504397); GLOW (NCT03653507)

Drug Class/Description:

Claudin 18.2-directed cytolytic antibody

Indications and Usage:

In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.   

Dosage Administration:

  • Administer by intravenous infusion only. Do not administer VYLOY as an intravenous push or bolus.
  • The recommended first dose of VYLOY is 800 mg/m2 followed by 600 mg/m2 every 3 weeks or 400 mg/m2 every 2 weeks."    

Dosage Forms and Strengths:

For injection: 100 mg lyophilized powder in a single-dose vial.    

Contraindications:

None.

Warnings and Precautions:

Hypersensitivity reactions including serious anaphylaxis reactions and serious and fatal infusion-related reactions have occurred. Monitor patients during and for at least 2 hours after infusion with VYLOY. Interrupt, slow the rate of infusion or permanently discontinue VYLOY based on severity and type of reaction. Premedicate with antihistamines for subsequent infusions after a hypersensitivity reaction.

Severe nausea and vomiting: Premedicate patients with antiemetics prior to each infusion. Interrupt or permanently discontinue VYLOY based on the severity of the nausea and/or vomiting. Manage patients during and after infusion with antiemetics or fluid replacement.

Adverse Reactions:

The most common adverse reactions (≥15%) for VYLOY in combination with mFOLFOX6 or CAPOX were nausea, vomiting, fatigue, decreased appetite, diarrhea, peripheral sensory neuropathy, abdominal pain, constipation, decreased weight, hypersensitivity reactions, and pyrexia.

The most common laboratory abnormalities (≥15%) for VYLOY in combination with mFOLFOX6 or CAPOX were decreased neutrophil count, decreased leucocyte count, decreased albumin, increased creatinine, decreased hemoglobin, increased glucose, decreased lymphocyte count, increased aspartate aminotransferase, decreased platelets, increased alkaline phosphatase, increased alanine aminotransferase, decreased glucose, decreased sodium, increased phosphate, decreased potassium, and decreased magnesium.

Use in Specific Populations:

Lactation: Advise not to breastfeed.

Adapted from:

https://www.astellas.com/us/system/files/vyloy_pi.pdf 

Every health-care provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications. The provider should always consult the most recent prescribing/product information. FDA Focus information is not guaranteed to be accurate, complete, or current. JADPRO and its editors, authors, reviewers, and commentators cannot be held responsible for any liability incurred as a consequence of the application of any of the information listed within.

More From FDA Focus

Scemblix (asciminib) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

October 29, 2024

Braftovi (encorafenib) with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

December 20, 2024

Sarclisa (isatuximab-irfc) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant

September 20, 2024

Advertisement
Current Issue
May/Jun 2025 Cover
May/Jun 2025 Cover Art
Vol 16 No 3 May/Jun 2025

Rare Diseases and Educational Tools for Advanced Practitioners

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO

May 15, 2025

A Pilot Program Implementing an Evidence-Based Walking Plan to Improve Cancer-Related Fatigue

Jennifer D. Bernt, DNP, FNP-C, AOCNP, Rita Million, PhD, RN, PHNA-BC, CNE, COI, Nicole S. Pham, MPH Et al.

May 15, 2025

Ductal Carcinoma In Situ Non Mass Enhancement on MRI 10 Years Before Mammographic Microcalcifications

Nancy W. Stead, MD, Andria P. Caton, RN, OCN, CHPN

May 15, 2025

Table of Contents Archive
JADPRO Logo
JADPRO's Facebook Account JADPRO's X Account JADPRO's LinkedIn Account
Submissions Subscribe

About

  • About Us
  • Society
  • Terms and Conditions
  • Privacy Policy
  • Advertise With JADPRO

Membership

  • Login

Conexiant Oncology Publications

  • The ASCO Post
  • JNCCN
  • JNCCN 360

Copyright © 2024 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.